Literature DB >> 10099817

The Crohn's Disease Activity Index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease.

E M Yoshida1.   

Abstract

The Crohn's Disease Activity Index (CDAI) has been used to measure Crohn's activity for over a quarter of a century. The development of the CDAI is reviewed and its reliability and validity are examined. Instruments used to assess Crohn's disease that were developed subsequent to the CDAI, including the Harvey-Bradshaw Index, the Cape Town Index and a three-variable version of the CDAI (modified for survey research), are similarly reviewed. The most recent instrument to assess Crohn's disease, the Inflammatory Bowel Disease Questionnaire, which assesses patients in the domains of bowel, systemic, emotional and social function, is also discussed.

Entities:  

Mesh:

Year:  1999        PMID: 10099817     DOI: 10.1155/1999/506915

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  24 in total

1.  Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density.

Authors:  M T Abreu; V Kantorovich; E A Vasiliauskas; U Gruntmanis; R Matuk; K Daigle; S Chen; D Zehnder; Y-C Lin; H Yang; M Hewison; J S Adams
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

2.  MCAM-expressing CD4(+) T cells in peripheral blood secrete IL-17A and are significantly elevated in inflammatory autoimmune diseases.

Authors:  Pradeep K Dagur; Angélique Biancotto; Lai Wei; H Nida Sen; Michael Yao; Warren Strober; Robert B Nussenblatt; J Philip McCoy
Journal:  J Autoimmun       Date:  2011-09-29       Impact factor: 7.094

3.  Impact of pain on health-related quality of life in patients with inflammatory bowel disease.

Authors:  Anja Schirbel; Anne Reichert; Stephanie Roll; Daniel C Baumgart; Carsten Büning; Bianca Wittig; Bertram Wiedenmann; Axel Dignass; Andreas Sturm
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

4.  Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.

Authors:  C Cuffari; S Hunt; T Bayless
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

Review 5.  Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Rachid Rafia; Alison Scope; Sue Harnan; John W Stevens; Matt Stevenson; Alan Lobo
Journal:  Pharmacoeconomics       Date:  2016-12       Impact factor: 4.981

6.  Anti-IgE treatment of eosinophil-associated gastrointestinal disorders.

Authors:  Shabnam Foroughi; Barbara Foster; Nayoung Kim; Leigh B Bernardino; Linda M Scott; Robert G Hamilton; Dean D Metcalfe; Peter J Mannon; Calman Prussin
Journal:  J Allergy Clin Immunol       Date:  2007-09       Impact factor: 10.793

7.  Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor.

Authors:  Saskia B Wortmann; Johan L K Van Hove; Terry G J Derks; Nathalie Chevalier; Vijaya Knight; Andreas Koller; Esmee Oussoren; Johannes A Mayr; Francjan J van Spronsen; Florian B Lagler; Sommer Gaughan; Emile Van Schaftingen; Maria Veiga-da-Cunha
Journal:  Blood       Date:  2020-08-27       Impact factor: 22.113

8.  PET-CT enteroclysis: a new technique for evaluation of inflammatory diseases of the intestine.

Authors:  Chandan Jyoti Das; Govind Makharia; Rakesh Kumar; Madhavi Chawla; Pooja Goswami; Raju Sharma; Arun Malhotra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-21       Impact factor: 9.236

9.  Crohn's disease: a two-year prospective study of the association between psychological distress and disease activity.

Authors:  Houssam E Mardini; Kevin E Kip; John W Wilson
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

10.  The effect of infliximab on extraintestinal manifestations of Crohn's disease.

Authors:  Ilana Kaufman; Dan Caspi; Dror Yeshurun; Iris Dotan; Michael Yaron; Ori Elkayam
Journal:  Rheumatol Int       Date:  2004-08-12       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.